
Stephen E. Jones
Examiner (ID: 2262, Phone: (571)272-1762 , Office: P/2842 )
| Most Active Art Unit | 2817 |
| Art Unit(s) | 2843, 2842, 2817 |
| Total Applications | 2057 |
| Issued Applications | 1739 |
| Pending Applications | 89 |
| Abandoned Applications | 263 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20425277
[patent_doc_number] => 20250387364
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-12-25
[patent_title] => ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN
[patent_app_type] => utility
[patent_app_number] => 19/308893
[patent_app_country] => US
[patent_app_date] => 2025-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8300
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19308893
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/308893 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | Aug 24, 2025 | Pending |
Array
(
[id] => 20393167
[patent_doc_number] => 20250368642
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-12-04
[patent_title] => SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND
[patent_app_type] => utility
[patent_app_number] => 19/281019
[patent_app_country] => US
[patent_app_date] => 2025-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19281019
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/281019 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Jul 24, 2025 | Pending |
Array
(
[id] => 20393168
[patent_doc_number] => 20250368643
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-12-04
[patent_title] => SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND
[patent_app_type] => utility
[patent_app_number] => 19/281069
[patent_app_country] => US
[patent_app_date] => 2025-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28374
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19281069
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/281069 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Jul 24, 2025 | Pending |
Array
(
[id] => 20348584
[patent_doc_number] => 20250345436
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-13
[patent_title] => USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS
[patent_app_type] => utility
[patent_app_number] => 19/276294
[patent_app_country] => US
[patent_app_date] => 2025-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11862
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19276294
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/276294 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | Jul 21, 2025 | Pending |
Array
(
[id] => 20335323
[patent_doc_number] => 20250339443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-06
[patent_title] => METHOD FOR TREATING OR PREVENTING CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL OR DISCOIDIN DOMAIN RECEPTOR 2 RELATED DISORDERS OR CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 19/271829
[patent_app_country] => US
[patent_app_date] => 2025-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6369
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19271829
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/271829 | METHOD FOR TREATING OR PREVENTING CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL OR DISCOIDIN DOMAIN RECEPTOR 2 RELATED DISORDERS OR CONDITIONS | Jul 16, 2025 | Pending |
Array
(
[id] => 20336449
[patent_doc_number] => 20250340569
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-06
[patent_title] => INHIBITORS OF KIF18A AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 19/272410
[patent_app_country] => US
[patent_app_date] => 2025-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41828
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 203
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19272410
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/272410 | INHIBITORS OF KIF18A AND USES THEREOF | Jul 16, 2025 | Pending |
Array
(
[id] => 20425269
[patent_doc_number] => 20250387356
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-12-25
[patent_title] => MIRDAMETINIB TREATMENT
[patent_app_type] => utility
[patent_app_number] => 19/237417
[patent_app_country] => US
[patent_app_date] => 2025-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21684
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19237417
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/237417 | MIRDAMETINIB TREATMENT | Jun 12, 2025 | Pending |
Array
(
[id] => 20226293
[patent_doc_number] => 12414932
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-16
[patent_title] => Arsinothricin and methods of treating infections using arsinothricin
[patent_app_type] => utility
[patent_app_number] => 19/176900
[patent_app_country] => US
[patent_app_date] => 2025-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 33
[patent_no_of_words] => 8356
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19176900
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/176900 | Arsinothricin and methods of treating infections using arsinothricin | Apr 10, 2025 | Issued |
Array
(
[id] => 20093344
[patent_doc_number] => 20250223280
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-10
[patent_title] => POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS
[patent_app_type] => utility
[patent_app_number] => 19/081912
[patent_app_country] => US
[patent_app_date] => 2025-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 124037
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19081912
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/081912 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | Mar 16, 2025 | Pending |
Array
(
[id] => 20068513
[patent_doc_number] => 20250206735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-26
[patent_title] => SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND
[patent_app_type] => utility
[patent_app_number] => 18/987568
[patent_app_country] => US
[patent_app_date] => 2024-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28621
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18987568
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/987568 | Synthesis of key intermediate of KRAS G12C inhibitor compound | Dec 18, 2024 | Issued |
Array
(
[id] => 19896375
[patent_doc_number] => 12274265
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-04-15
[patent_title] => Emulsifiable neonicotinoid pesticide concentrate
[patent_app_type] => utility
[patent_app_number] => 18/968074
[patent_app_country] => US
[patent_app_date] => 2024-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 5
[patent_no_of_words] => 5252
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18968074
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/968074 | Emulsifiable neonicotinoid pesticide concentrate | Dec 3, 2024 | Issued |
Array
(
[id] => 19890293
[patent_doc_number] => 20250115605
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-10
[patent_title] => AZAINDOLE ROCK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/915221
[patent_app_country] => US
[patent_app_date] => 2024-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18915221
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/915221 | Azaindole rock inhibitors | Oct 13, 2024 | Issued |
Array
(
[id] => 19960257
[patent_doc_number] => 12329729
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-06-17
[patent_title] => Method of treating cancer in a subject
[patent_app_type] => utility
[patent_app_number] => 18/895223
[patent_app_country] => US
[patent_app_date] => 2024-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 5745
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18895223
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/895223 | Method of treating cancer in a subject | Sep 23, 2024 | Issued |
Array
(
[id] => 19809452
[patent_doc_number] => 12240822
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-04
[patent_title] => Naphthalene isoxazoline compound and application thereof
[patent_app_type] => utility
[patent_app_number] => 18/820199
[patent_app_country] => US
[patent_app_date] => 2024-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 6426
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18820199
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/820199 | Naphthalene isoxazoline compound and application thereof | Aug 28, 2024 | Issued |
Array
(
[id] => 19570264
[patent_doc_number] => 20240374556
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/782646
[patent_app_country] => US
[patent_app_date] => 2024-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25479
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18782646
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/782646 | Administration of benzodiazepine compositions | Jul 23, 2024 | Issued |
Array
(
[id] => 19614818
[patent_doc_number] => 20240400498
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => PRODRUGS OF ITACONATE AND METHYL ITACONATE
[patent_app_type] => utility
[patent_app_number] => 18/777888
[patent_app_country] => US
[patent_app_date] => 2024-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16540
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18777888
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/777888 | Prodrugs of itaconate and methyl itaconate | Jul 18, 2024 | Issued |
Array
(
[id] => 19691189
[patent_doc_number] => 20250009734
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => METHODS OF INHIBITING FOXO1 FOR TREATMENT OF LYMPHATIC DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/757228
[patent_app_country] => US
[patent_app_date] => 2024-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10731
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18757228
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/757228 | METHODS OF INHIBITING FOXO1 FOR TREATMENT OF LYMPHATIC DISORDERS | Jun 26, 2024 | Pending |
Array
(
[id] => 19418351
[patent_doc_number] => 20240294474
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/644728
[patent_app_country] => US
[patent_app_date] => 2024-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39928
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18644728
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/644728 | Lipids and nanoparticle compositions thereof | Apr 23, 2024 | Issued |
Array
(
[id] => 19387814
[patent_doc_number] => 20240277684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION
[patent_app_type] => utility
[patent_app_number] => 18/638133
[patent_app_country] => US
[patent_app_date] => 2024-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638133
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/638133 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | Apr 16, 2024 | Pending |
Array
(
[id] => 19417252
[patent_doc_number] => 20240293375
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS
[patent_app_type] => utility
[patent_app_number] => 18/629056
[patent_app_country] => US
[patent_app_date] => 2024-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629056
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/629056 | Methods and compositions for treating glucocorticoid excess | Apr 7, 2024 | Issued |